Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for
            <i>In Vitro</i>
            Antifungal Susceptibility Testing of Cryptococcus neoformans

Delma, Fatima Zohra; Al‐Hatmi, Abdullah M. S.; Buil, Jochem B.; Lee, Hein van der; Tehupeiory-Kooreman, Marlou; Hoog, G. Sybren de; Meletiadis, Joseph; Verweij, Paul E.

doi:10.1128/aac.02261-19

Cited by 16 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jesu’s Guinea 22 reported that Sensititre YeastOne was suitable for the analysis of A. fumigatus itraconazole and voriconazole MICs when results were assessed at 48 h of incubation. Fatima Zohra Delma 23 reported essential agreement between Sensititre YeastOne and EUCAST/CLSI for amphotericin B, 5-flucytosine, fluconazole, and voriconazole with >89%/>93% for MTS and for EUCAST/CLSI 57%/>75%. Major error rates are low for amphotericin B and fluconazole (<3%) and a bit higher for the other drugs (<8%).…”

Section: Discussionmentioning

confidence: 96%

MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China)

Fang¹,

Liu²,

Huang³

et al. 2022

IDR

View full text Add to dashboard Cite

Introduction Talaromyces marneffei is a life-threatening pathogen that causes systemic talaromycosis in immunocompromised and acquired immunodeficiency syndrome (AIDS) patients. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) as a tool to cluster T. marneffei isolates is rarely reported and the data on antifungal susceptibility of T. marneffei isolated in the southern region of China, especially in Fujian, is hardly found. Methods MALDI-TOF MS was used to cluster 135 T. marneffei isolates, and the minimum inhibitory concentration (MIC) values of amphotericin B, itraconazole, posaconazole, voriconazole, fluconazole, anidulafungin, micafungin, caspofungin and 5-fluorocytosine with Sensititre YeastOne™ YO10 assay were measured during January 2017 to October 2020 in Fujian and Guangxi. Results MALDI-TOF MS correctly identified 100% of the T. marneffei isolates. Hierarchical clustering of MALDI-TOF peak profiles identified four different clusters. MICs for itraconazole, posaconazole, voriconazole and amphotericin B were as follows: ≤0.015–0.03 μg/mL, ≤0.008–0.03 μg/mL, ≤0.008–0.06 μg/mL, ≤0.12–1 μg/mL, respectively. MICs for echinocandins and fluconazole were comparatively high. Conclusion Since only simple sample preparation is required and since results are available in a short period of time, MALDI-TOF MS can be considered as a method for identification and clustering of T. marneffei . Itraconazole, posaconazole, voriconazole and amphotericin B can be used to treat T. marneffei infected patients due to the low MICs.

show abstract

Section: Discussionmentioning

confidence: 96%

MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China)

Fang¹,

Liu²,

Huang³

et al. 2022

IDR

View full text Add to dashboard Cite

show abstract

“…Recently, a new low-cost four-well plate agar method is suitable for echinocandin susceptibility screening of Aspergillus species and can be used to detect echinocandin non-WT isolates [ 185 ]. Moreover, MIC test strip and Sensititre YeastOne showed an overall agreement of >72% and >94% at ±1 and ±2 dilutions when compared to CLSI and EUCAST broth microdilution methods, respectively [ 186 ].…”

Section: Antifungal Susceptibility Testing: Current Paradigm Chalmentioning

confidence: 99%

Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium

et al. 2020

View full text Add to dashboard Cite

The high clinical mortality and economic burden posed by invasive fungal infections (IFIs), along with significant agricultural crop loss caused by various fungal species, has resulted in the widespread use of antifungal agents. Selective drug pressure, fungal attributes, and host- and drug-related factors have counteracted the efficacy of the limited systemic antifungal drugs and changed the epidemiological landscape of IFIs. Species belonging to Candida, Aspergillus, Cryptococcus, and Pneumocystis are among the fungal pathogens showing notable rates of antifungal resistance. Drug-resistant fungi from the environment are increasingly identified in clinical settings. Furthermore, we have a limited understanding of drug class-specific resistance mechanisms in emerging Candida species. The establishment of antifungal stewardship programs in both clinical and agricultural fields and the inclusion of species identification, antifungal susceptibility testing, and therapeutic drug monitoring practices in the clinic can minimize the emergence of drug-resistant fungi. New antifungal drugs featuring promising therapeutic profiles have great promise to treat drug-resistant fungi in the clinical setting. Mitigating antifungal tolerance, a prelude to the emergence of resistance, also requires the development of effective and fungal-specific adjuvants to be used in combination with systemic antifungals.

show abstract

“…Second, we recommend comparing the MICs to existing MIC distributions for that drug and species to determine if the MIC is most likely "normal" or "elevated" (indicating possible acquired resistance). In Tables 4-7, we summarised our data for more than 4000 isolates and documented alignment to published EUCAST data [25,[34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52] (for details on this data, see Supplementary Text S2). These tables can be used for comparison if the local susceptibility testing is confirmed to align with EUCAST testing.…”

Section: General Considerationsmentioning

confidence: 99%

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints

Astvad

Arıkan-Akdağlı

Arendrup

2022

JoF

View full text Add to dashboard Cite

EUCAST has established clinical breakpoints for the six most common Candida species and Cryptococcus neoformans but not for less common yeasts because sufficient evidence is lacking. Consequently, the question “How to interpret the MIC?” for other yeasts often arises. We propose a pragmatic classification for amphotericin B, anidulafungin, fluconazole, and voriconazole MICs against 30 different rare yeasts. This classification takes advantage of MIC data for more than 4000 isolates generated in the EUCAST Development Laboratory for Fungi validated by alignment to published EUCAST MIC data. The classification relies on the following two important assumptions: first, that when isolates are genetically related, pathogenicity and intrinsic susceptibility patterns may be similar; and second, that even if species are not phylogenetically related, the rare yeasts will likely respond to therapy, provided the MIC is comparable to that against wild-type isolates of more prevalent susceptible species because rare yeasts are most likely “rare” due to a lower pathogenicity. In addition, the treatment recommendations available in the current guidelines based on the in vivo efficacy data and clinical experience are taken into consideration. Needless to say, it is of utmost importance (a) to ascertain that the species identification is correct (using MALDI-TOF or sequencing), and (b) to re-test the isolate once or twice to confirm that the MIC is representative for the isolate (because of the inherent variability in MIC determinations). We hope this pragmatic guidance is helpful until evidence-based EUCAST breakpoints can be formally established.

show abstract

Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans

Cited by 16 publications

References 23 publications

MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China)

MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China)

Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints

Contact Info

Product

Resources

About